Free tool
Drug Trial Radar: Psychiatry
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
272
Completed, industry sponsors, Psychiatry, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed272
272 trials
Showing 1 to 25, recently updated first.
Wanbangde Pharmaceutical Group Co., LTDIndustry
NCT04529148 · 74 participants · Start Nov 30, 2020 · Primary completion Aug 18, 2022
Drug: Ginkgo biloba dropping pills,best western medicine treatment; Mimetic drug of ginkgo biloba dropping pills,best western medicine treatment · For: Stable Angina Pectoris Associated With Depression
Sites: Foshan, China; Guangzhou, China; Shenzhen, China · 4 sites in all
BioXcel Therapeutics IncIndustry
NCT06041646 · 29 participants · Start Oct 2, 2023 · Primary completion Apr 29, 2024
Drug: Sublingual film containing Igalmi · For: Bipolar Disorder; Schizophrenia; Agitation,Psychomotor and 2 more
Sites: Little Rock, Arkansas; Rogers, Arkansas
- A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant DepressionCompleted
Janssen Korea, Ltd., KoreaJohnson & Johnson (Janssen) (JNJ)
NCT07053345 · 47 participants · Start Jun 9, 2025 · Primary completion Jul 13, 2026
Drug: Esketamine 56 mg; Esketamine 84 mg · For: Depressive Disorder, Treatment-Resistant
Sites: Goyang Si Gyeonggi Do, South Korea; Iksan, South Korea; Seoul, South Korea · 6 sites in all
- A Switch Study of BMS-337039 in Schizophrenic Out-patientsPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00232687 · 450 participants · Start Jun 1, 2005 · Primary completion Apr 1, 2007
Drug: Aripiprazole; Aripiprazole · For: Schizophrenia
Sites: Hall in Tirol, Austria; Vienna, Austria; Bruges, Belgium · 72 sites in all
Johnson & Johnson Taiwan LtdJohnson & Johnson (Janssen) (JNJ)
NCT00526877 · 31 participants · Start Jul 13, 2007 · Primary completion Jan 31, 2009
Drug: Risperidone · For: Schizophrenia; Schizoaffective Disorders
Sites: Taipei, Taiwan
- A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed EpisodePivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00277212 · 1,169 participants · Start Dec 1, 2005 · Primary completion Jul 1, 2009
Drug: Lamotrigine + Aripiprazole; Lamotrigine + Placebo · For: Bipolar Disorder
Sites: Birmingham, Alabama; Tucson, Arizona; Anaheim, California · 66 sites in all
Corium, Inc.Industry
NCT05721235 · 123 participants · Start Jun 2, 2023 · Primary completion Jul 31, 2025
Drug: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) · For: Attention Deficit/Hyperactivity Disorder
Sites: Little Rock, Arkansas; Anaheim, California; Centennial, Colorado · 20 sites in all
- A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT04085172 · 396 participants · Start Sep 18, 2019 · Primary completion Sep 2, 2025
Drug: Guanfacine hydrochloride (TAK-503); Atomoxetine hydrochloride · For: Attention Deficit Hyperactivity Disorder
Sites: Dothan, Alabama; Anaheim, California; Imperial, California · 50 sites in all
Supernus Pharmaceuticals, Inc.Industry
NCT06185985 · 161 participants · Start Mar 25, 2024 · Primary completion Dec 3, 2024
Drug: SPN-812 · For: Attention-Deficit/Hyperactivity Disorder
Sites: New York, New York
- Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk UsersPivotal-lookingCompleted
Indivior Inc.Industry
NCT04995029 · 785 participants · Start Oct 26, 2021 · Primary completion Jun 26, 2024
Drug: Transmucosal Buprenorphine; Extended-release Buprenorphine · For: Moderate to Severe Opioid-use Disorder
Sites: Garden Grove, California; Panorama City, California; San Diego, California · 29 sites in all
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT05859698 · 59 participants · Start May 9, 2023 · Primary completion Dec 27, 2024
Drug: Valbenazine · For: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder and 2 more
Sites: Bryant, Arkansas; Anaheim, California; Orange, California · 18 sites in all
Janssen-Cilag Ltd.Johnson & Johnson (Janssen) (JNJ)
NCT04829318 · 183 participants · Start Apr 26, 2021 · Primary completion Jul 22, 2024
Drug: Esketamine; SSRI/SNRI · For: Depressive Disorder, Major
Sites: Buenos Aires, Argentina; Córdoba, Argentina; La Plata, Argentina · 59 sites in all
- A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home SettingCompleted
Supernus Pharmaceuticals, Inc.Industry
NCT05059600 · 52 participants · Start Oct 8, 2021 · Primary completion Jul 14, 2022
Drug: ZULRESSO® · For: Postpartum Depression
Sites: Culver City, California; Miramar, Florida; Pompano Beach, Florida · 6 sites in all
- An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHDPivotal-lookingCompleted
Corium, Inc.Industry
NCT05685732 · 246 participants · Start Mar 22, 2023 · Primary completion May 2, 2024
Drug: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) · For: Attention Deficit/Hyperactivity Disorder
Sites: Little Rock, Arkansas; Anaheim, California; Centennial, Colorado · 20 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03713658 · 34 participants · Start Oct 18, 2018 · Primary completion Dec 2, 2019
Drug: Risperidone 3 mg; Paliperidone Palmitate 50 mg eq. and 7 more · For: Schizophrenia
Sites: Kigali, Rwanda; Musanze District, Rwanda; Ngoma District, Rwanda
Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
NCT04940039 · 93 participants · Start Jul 22, 2021 · Primary completion Apr 16, 2024
Drug: Risperidone 3 mg; Paliperidone Palmitate 50 mg eq. and 7 more · For: Schizophrenia
Sites: Butare, Rwanda; Kibuye, Rwanda; Kigali, Rwanda · 5 sites in all
- A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant DepressionPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04599855 · 477 participants · Start Nov 4, 2020 · Primary completion Jan 31, 2024
Drug: Esketamine 56 mg; Esketamine 84 mg and 1 more · For: Depressive Disorder, Treatment-Resistant
Sites: Birmingham, Alabama; Huntsville, Alabama; Little Rock, Arkansas · 54 sites in all
- SUBLOCADE Rapid Initiation StudyCompleted
Indivior Inc.Industry
NCT03993392 · 26 participants · Start Aug 29, 2019 · Primary completion Dec 26, 2019
Drug: TM buprenorphine; SUBLOCADE · For: Opioid-use Disorder
Sites: Berlin, New Jersey
Indivior Inc.Industry
NCT04060654 · 17 participants · Start Oct 21, 2019 · Primary completion May 15, 2020
Drug: Sublocade · For: Opioid Use Disorder, Severe; Opioid Use Disorder, Moderate
Sites: Berlin, New Jersey
- Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection LocationsPivotal-lookingCompleted
Indivior Inc.Industry
NCT05704543 · 132 participants · Start Mar 1, 2023 · Primary completion Nov 1, 2023
Drug: Buprenorphine Extended-Release Injection · For: Opioid Use Disorder
Sites: San Diego, California; Hollywood, Florida; Miami Lakes, Florida · 6 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01527305 · 212 participants · Start Jun 22, 2012 · Primary completion Dec 31, 2013
Drug: Paliperidone palmitate · For: Schizophrenia
Sites: Huzhou, China; Shanghai, China; Shantou, China · 21 sites in all
- Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHDCompleted
Supernus Pharmaceuticals, Inc.Industry
NCT04786990 · 96 participants · Start Jul 27, 2021 · Primary completion May 23, 2023
Drug: SPN-812 · For: Attention-Deficit/Hyperactivity Disorder (ADHD)
Sites: Little Rock, Arkansas; Orange, California; Miami, Florida · 17 sites in all
- The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With SchizophreniaPivotal-lookingCompleted
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.Industry
NCT05011669 · 200 participants · Start Aug 16, 2021 · Primary completion Apr 16, 2023
Drug: Lurasidone · For: Schizophrenia
Sites: Beijing, China
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT04830215 · 122 participants · Start Apr 1, 2021 · Primary completion May 27, 2022
Drug: Brexpiprazole · For: Major Depressive Disorder
Sites: Chatham, Canada
NovartisNovartis (NVS)
NCT00154323 · 55 participants · Start Jan 2003 · Primary completion Jan 2006
Drug: Oxcarbazepine · For: Bipolar Disorder
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.